First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
16
07
2023
medline:
6
9
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
MHV370, a dual antagonist of human Toll-like receptors (TLR) 7 and 8, suppresses cytokines and interferon-stimulated genes in vitro and in vivo, and has demonstrated efficacy in murine models of lupus. This first-in-human study aimed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of MHV370 in healthy adults, as well as the effects of food consumption on a single dose of MHV370. This was a phase 1, randomised, placebo-controlled study conducted in three parts. In part A, participants received (3:1) a single ascending dose (SAD) of 1, 3, 10, 20, 40, 80, 160, 320, 640 and 1000 mg MHV370 or placebo. In part B, participants received (3:1) multiple ascending doses (MAD) of 25, 50, 100, 200 and 400 mg MHV370 twice daily (b.i.d) or placebo for 14 days. In part C, participants received an open-label single dose of 200 mg MHV370 under fasted or fed conditions. Safety, pharmacokinetic and pharmacodynamic parameters were evaluated. MHV370 was well tolerated, and no safety signal was observed in the study. No dose-limiting adverse events occurred across the dose range evaluated. Plasma concentrations of MHV370 increased with dose (mean [SD] maximum plasma concentrations ranged from 0.97 [0.48] to 1670 [861.0] ng/mL for SAD of 3-1000 mg, 29.5 [7.98] to 759 [325.0] ng/mL for MAD of 25-400 mg b.i.d. on day 1). The intake of food did not have a relevant impact on the pharmacokinetics of MHV370. Pharmacodynamic data indicated time- and dose-dependent inhibition of TLR7-mediated CD69 expression on B cells (100% inhibition at 24 h post-dose starting from SAD 160 mg and MAD 50 mg b.i.d.) and TLR8-mediated TNF release after ex vivo stimulation (>90% inhibition at 24 h post-dose starting from SAD 320 mg and MAD 100 mg b.i.d.). The safety, pharmacokinetic and pharmacodynamic data support the further development of MHV370 in systemic autoimmune diseases driven by the overactivation of TLR7 and TLR8.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
MHV370, a dual antagonist of human Toll-like receptors (TLR) 7 and 8, suppresses cytokines and interferon-stimulated genes in vitro and in vivo, and has demonstrated efficacy in murine models of lupus. This first-in-human study aimed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of MHV370 in healthy adults, as well as the effects of food consumption on a single dose of MHV370.
METHODS
METHODS
This was a phase 1, randomised, placebo-controlled study conducted in three parts. In part A, participants received (3:1) a single ascending dose (SAD) of 1, 3, 10, 20, 40, 80, 160, 320, 640 and 1000 mg MHV370 or placebo. In part B, participants received (3:1) multiple ascending doses (MAD) of 25, 50, 100, 200 and 400 mg MHV370 twice daily (b.i.d) or placebo for 14 days. In part C, participants received an open-label single dose of 200 mg MHV370 under fasted or fed conditions. Safety, pharmacokinetic and pharmacodynamic parameters were evaluated.
RESULTS
RESULTS
MHV370 was well tolerated, and no safety signal was observed in the study. No dose-limiting adverse events occurred across the dose range evaluated. Plasma concentrations of MHV370 increased with dose (mean [SD] maximum plasma concentrations ranged from 0.97 [0.48] to 1670 [861.0] ng/mL for SAD of 3-1000 mg, 29.5 [7.98] to 759 [325.0] ng/mL for MAD of 25-400 mg b.i.d. on day 1). The intake of food did not have a relevant impact on the pharmacokinetics of MHV370. Pharmacodynamic data indicated time- and dose-dependent inhibition of TLR7-mediated CD69 expression on B cells (100% inhibition at 24 h post-dose starting from SAD 160 mg and MAD 50 mg b.i.d.) and TLR8-mediated TNF release after ex vivo stimulation (>90% inhibition at 24 h post-dose starting from SAD 320 mg and MAD 100 mg b.i.d.).
CONCLUSION
CONCLUSIONS
The safety, pharmacokinetic and pharmacodynamic data support the further development of MHV370 in systemic autoimmune diseases driven by the overactivation of TLR7 and TLR8.
Identifiants
pubmed: 37532923
doi: 10.1007/s13318-023-00847-3
pii: 10.1007/s13318-023-00847-3
pmc: PMC10480294
doi:
Substances chimiques
Toll-Like Receptor 7
0
Toll-Like Receptor 8
0
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
553-566Informations de copyright
© 2023. The Author(s).
Références
Immunity. 2016 Apr 19;44(4):739-54
pubmed: 27096317
Nat Rev Immunol. 2015 Sep 15;15(9):529-44
pubmed: 26292638
Nature. 2022 May;605(7909):349-356
pubmed: 35477763
Cell Rep Med. 2023 May 16;4(5):101036
pubmed: 37196635
J Pharmacol Exp Ther. 2021 Mar;376(3):397-409
pubmed: 33328334
Immunity. 2007 Nov;27(5):801-10
pubmed: 17997333
Nat Rev Rheumatol. 2021 Feb;17(2):98-108
pubmed: 33339987
Arthritis Rheum. 2007 Oct;56(10):3379-86
pubmed: 17907192
Int J Inflam. 2017;2017:8391230
pubmed: 28553556
J Exp Med. 2013 Dec 16;210(13):2903-19
pubmed: 24277153
J Am Soc Nephrol. 1995 Aug;6(2):257-63
pubmed: 7579093
Pharmacol Res Perspect. 2021 Oct;9(5):e00842
pubmed: 34414672
Trends Mol Med. 2007 Nov;13(11):460-9
pubmed: 18029230
Nephron. 2018;140(1):1-8
pubmed: 29772565
Immunol Rev. 2007 Dec;220:225-36
pubmed: 17979850
Nat Immunol. 2001 Aug;2(8):675-80
pubmed: 11477402
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413140
Clin Kidney J. 2016 Oct;9(5):682-99
pubmed: 27679715